

Aptus Pharma Limited

Connecting.....Life



www.aplus-pharma.com | info@apluspharma.com | export@apluspharma.com | +91 76004 27827

Date: November 12, 2025

To,

The Manager,
Listing Compliance Department,
BSE Limited,
P. J. Towers, Dalal Street,
Mumbai – 400 001.

Scrip Code: 544529

ISIN: INE15XJ01010

Subject: Submission of Monitoring Agency Report for Utilization of Public Issue Proceeds for the quarter ended 30th September, 2025 pursuant to Regulation 32(6) of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,


Pursuant to Regulation 262(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the **Monitoring Agency Report** for the quarter ended 30th September, 2025 issued CARE Ratings Limited showing **NIL deviation** in respect of the utilization of proceeds of the Public Issue of the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully

For Aptus Pharma Limited,


Tejash Maheshchandra Hathi
Managing Director
DIN: 03151221



Encl.: Monitoring Agency Report for the quarter ended 30th September, 2025

